A new "black cheque" company that claims to be the first in Europe devoted to biomanufacturing has been set up by a team of investors, including former Sanofi chief executive Gerard le Fur.
Sanofi has completed the spin-out of its pharma ingredients business EuroAPI, with shares in the new company rising more than 3% on its starting price of €12 in early trading on the Euronex
The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead.